Amprion

Amprion Inc is an emerging biotechnology company developing novel diagnostics for neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease and Lewy body Dementia. The company is developing a diagnostic platform called Seed Amplification Assay (SAA) and the first test, which is marketed under the brand name SynTap, is being offered to physicians and hospital systems under the CAP/CLIA regulatory regime since 2021. The FDA awarded Amprion a “Breakthrough Device Designation” for its SynTap test.

Vanreusel Ventures and the CFO services they offer have been instrumental in helping us transition from a science-driven, pre-revenue company to a revenue-generating and ultimately profitable company. Vanreusel was referred to us through a trusted colleague, and we engaged them to professionalize our financial control and projection capabilities at a time when the company was not yet in a position to hire a full-time CFO.

As a first project, Vanreusel developed an extensive forward-looking 5 year financial model, including revenue, P&L, balance sheet and cashflow projections. This model was crucial in properly assessing the capital requirements of the company for the next phase of revenue growth to the point of profitability and beyond. The financial model was also instrumental in attracting Series B investors to fund the growth phase of the company. Throughout this project, Vanreusel Ventures was extremely responsive to requests for information in response to investor diligence questions, often on very short-notice, and Vanreusel modeled various financing scenarios with equity and debt components that let Amprion’s management team chart the best course for the company with reliable information and projections. Importantly, it gave the Amprion management team the confidence that we had financial projections that would withstand serious scrutiny under investor diligence.

With the financing round secured, we are now looking to expand our work with Vanreusel. The Amprion management team will be held accountable to reaching revenue targets, and we need to carefully balance and project revenue against expenses and headcount growth to reach profitability within 18 to 24 months. We have absolute confidence in Vanreusel to provide Amprion with professional, state-of-the-art financial controls to manage this stage of company growth successfully. Importantly, working with Vanreusel will allow Amprion to operate in a hybrid model, with mid-level financial expertise in-house at Amprion, while the CFO function will be performed by Vanreusel. Our collaboration with Vanreusel gives Amprion access to a seasoned, high-level CFO with a long track record, which is a luxury few emerging companies of Amprion’s size can afford or attract.